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Cell culture is a complex and dynamic process. Efficient optimisation of economic production, process risk and 
product quality requires an integrated approach comprising both experimentation and modelling; dynamic 
mechanistic models offer the benefits of a mechanistic understanding of processes and can potentially predict 
counter-intuitive outcomes over extended time periods. Further, cost and control optimisation also requires 
appropriately scaleable production systems with discrete control of potent and costly signalling factors. 
Haematopoietic cultures are ideal systems to develop such approaches; suspension culture ensures 
compatibility with scaleable well controlled platforms and high frequency cell sampling for high resolution time 
series. Haematopoietic cultures also have high clinical potential from haematopoietic stem cell transplants to 
manufactured red cells, platelets or immunotherapies. 
 
Dynamic mechanistic models are underutilised in the bioprocess community partly due to the skills barrier to 
entry. A multidisciplinary collaboration has designed a software interface for the description, testing and 
manipulation of hypothetical mechanistic dynamic models. The approach aims for parsimonious, and hence 
testable, models built on the dominant phenomena involved in cell culture (e.g. substrate-dependent growth, cell 
death). We have demonstrated the application of the software in the context of a hypothesis-driven programme 
of research to determine the productivity limits of human erythroblast culture from cord blood CD34+ cells; the 
software enabled a team of biologists to develop a low parameter predictive deterministic model of the effects of 
medium supply and cell density control strategies on erythroblast growth that could optimise cells/$ production 
for any given facility time and medium volume cost. Relatively small shifts in strategy had greater than 3-fold 
impact on cost and substantially changed the impact of imprecision in timing of process operations. We have 
further demonstrated how the software and models are complementary to a novel immobilised growth factor 
technology for scaleable haematopoietic expansion. Immobilisation of multiple haematopoietic factors on 
magnetic beads increases the dimensions of control in the culture system and decouples growth factor 
dynamics from basic medium supply. Further, immobilised factors are shown to be orders of magnitude more 
potent than their soluble counterparts and remain functional under mechanically mixed, and hence scalable, 
conditions. Such increased control opportunities and system intensification will increase the potential benefit and 
power of mechanistic modelling approaches in manufacturing of cell based therapies. 
 
